In all first-line randomized clinical trials (RCTs) with previously untreated ALK TKIs in patients with advanced NSCLC with ALK fusion, at least 40% of the patients in the experimental arm did not receive a further treatment at progression, likely due to a rapid change in performance status and the progression of the disease [36,37,38]. Here, ALK is linked to non-small cell lung carcinoma.